These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11584998)

  • 21. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
    Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
    Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
    Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
    Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
    Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
    Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of platinum-resistant ovarian cancer.
    Trimble EL; Wright J; Christian MC
    Expert Opin Pharmacother; 2001 Aug; 2(8):1299-306. PubMed ID: 11584998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Epithelial ovarian cancer].
    Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
    Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive surgery in the management of ovarian cancer.
    Schwartz PE
    Oncology (Williston Park); 2008 Aug; 22(9):1025-33; discussion 1033-8, 1041, 1045. PubMed ID: 18777954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
    Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM
    Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H; Changchien CC
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer.
    Boere IA; van der Burg ME
    Curr Pharm Des; 2012; 18(25):3741-53. PubMed ID: 22591417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Webber K; Friedlander M
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():126-138. PubMed ID: 28027849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing treatment in recurrent epithelial ovarian cancer.
    Corrado G; Salutari V; Palluzzi E; Distefano MG; Scambia G; Ferrandina G
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1147-1158. PubMed ID: 29086618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trials and future potential of targeted therapy for ovarian cancer.
    Itamochi H; Kigawa J
    Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.
    Chuang YT; Chang CL
    Taiwan J Obstet Gynecol; 2012 Sep; 51(3):336-41. PubMed ID: 23040913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
    Colombo N
    Future Oncol; 2013 Dec; 9(12 Suppl):19-23. PubMed ID: 24195526
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.